Screening log: Challenges in community patient recruitment for gynecologic oncology clinical trials.

Clinical trials Electronic screening Gynecologic oncology Patient recruitment

Journal

Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157

Informations de publication

Date de publication:
Dec 2024
Historique:
received: 23 04 2024
revised: 25 09 2024
accepted: 27 09 2024
medline: 18 10 2024
pubmed: 18 10 2024
entrez: 18 10 2024
Statut: epublish

Résumé

Clinical trial participation can improve overall survival and mitigate healthcare disparities for gynecologic cancer patients in low-volume community centers. This study aimed to assess the effectiveness of a centrally regulated but administratively decentralized electronic screening log system to identify eligible patients across a large catchment area for a National Cancer Institute (NCI)-designated cancer center's open clinical trials. Electronic screening log data collected between 2014 and 2021 from ten community partner sites in a single NCI-designated cancer center's catchment area were reviewed retrospectively. Clinical factors assessed included cancer site, primary versus recurrent disease status, and histology. Identification efficiency (the ratio of patients screened identified with an available trial) was calculated. Identification inefficiencies (failures to identify patients with a potentially relevant trial) were assessed, and etiologies were characterized. Across ten community partner sites, 492 gynecologic cancer patients were screened for seven open clinical trials during the study period. This included 170 (34.5 %) ovarian cancer patients, 156 (31.7 %) endometrial cancer patients, and 119 (24.2 %) cervical cancer patients. Over 40 % had advanced stage disease, and 10.6 % had recurrent disease. Only three patients were identified as having a relevant open trial; none ultimately enrolled due to not meeting trial eligibility criteria. An additional 2-52 patients were retrospectively found to have a relevant trial available despite not being identified as such within the electronic screening log system. Up to 14.4 % of patients had one or more missing minimum data elements that hindered full evaluation of clinical trial availability. Re-screening patients when new trials open may identify 12-15 additional patients per recurrent disease trial. An electronic screening log system can increase awareness of gynecologic oncology clinical trials at a NCI-designated cancer center's community partner sites. However, it is inadequate as a single intervention to increase clinical trial enrollment. Providing adequate support staff, documenting clinical factors consistently, re-screening patients at relevant intervals, and coordinating with central study personnel may increase its utility.

Sections du résumé

Background UNASSIGNED
Clinical trial participation can improve overall survival and mitigate healthcare disparities for gynecologic cancer patients in low-volume community centers. This study aimed to assess the effectiveness of a centrally regulated but administratively decentralized electronic screening log system to identify eligible patients across a large catchment area for a National Cancer Institute (NCI)-designated cancer center's open clinical trials.
Methods UNASSIGNED
Electronic screening log data collected between 2014 and 2021 from ten community partner sites in a single NCI-designated cancer center's catchment area were reviewed retrospectively. Clinical factors assessed included cancer site, primary versus recurrent disease status, and histology. Identification efficiency (the ratio of patients screened identified with an available trial) was calculated. Identification inefficiencies (failures to identify patients with a potentially relevant trial) were assessed, and etiologies were characterized.
Results UNASSIGNED
Across ten community partner sites, 492 gynecologic cancer patients were screened for seven open clinical trials during the study period. This included 170 (34.5 %) ovarian cancer patients, 156 (31.7 %) endometrial cancer patients, and 119 (24.2 %) cervical cancer patients. Over 40 % had advanced stage disease, and 10.6 % had recurrent disease. Only three patients were identified as having a relevant open trial; none ultimately enrolled due to not meeting trial eligibility criteria. An additional 2-52 patients were retrospectively found to have a relevant trial available despite not being identified as such within the electronic screening log system. Up to 14.4 % of patients had one or more missing minimum data elements that hindered full evaluation of clinical trial availability. Re-screening patients when new trials open may identify 12-15 additional patients per recurrent disease trial.
Conclusions UNASSIGNED
An electronic screening log system can increase awareness of gynecologic oncology clinical trials at a NCI-designated cancer center's community partner sites. However, it is inadequate as a single intervention to increase clinical trial enrollment. Providing adequate support staff, documenting clinical factors consistently, re-screening patients at relevant intervals, and coordinating with central study personnel may increase its utility.

Identifiants

pubmed: 39421148
doi: 10.1016/j.conctc.2024.101379
pii: S2451-8654(24)00126-1
pmc: PMC11483309
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101379

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Rubina Ratnaparkhi (R)

University of Kansas, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, 3901 Rainbow Boulevard, Kansas City, KS, 66160, United States.

Gary C Doolittle (GC)

University of Kansas Cancer Center, 4001 Rainbow Boulevard, Kansas City, KS, 66160, United States.
Masonic Cancer Alliance, 4350 Shawnee Mission Parkway, Fairway, KS, 66205, United States.

Hope Krebill (H)

University of Kansas Cancer Center, 4001 Rainbow Boulevard, Kansas City, KS, 66160, United States.
Masonic Cancer Alliance, 4350 Shawnee Mission Parkway, Fairway, KS, 66205, United States.

Michelle Springer (M)

University of Kansas Cancer Center, 4001 Rainbow Boulevard, Kansas City, KS, 66160, United States.
Masonic Cancer Alliance, 4350 Shawnee Mission Parkway, Fairway, KS, 66205, United States.

Elizabeth Calhoun (E)

University of Illinois Chicago, Office of the Vice Chancellor for Health Affairs, 914 S. Wood St., Chicago, IL, 60612, United States.

Andrea Jewell (A)

University of Kansas, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, 3901 Rainbow Boulevard, Kansas City, KS, 66160, United States.
University of Kansas Cancer Center, 4001 Rainbow Boulevard, Kansas City, KS, 66160, United States.

Dinesh Pal Mudaranthakam (DP)

University of Kansas Cancer Center, 4001 Rainbow Boulevard, Kansas City, KS, 66160, United States.

Classifications MeSH